Sit Investment Associates Inc. reduced its stake in shares of Becton Dickinson and Co. (NYSE:BDX) by 55.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 138,140 shares of the company’s stock after selling 169,700 shares during the period. Sit Investment Associates Inc. owned about 0.07% of Becton Dickinson and worth $23,427,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Fund Advisors boosted its position in shares of Becton Dickinson and by 9.5% in the first quarter. BlackRock Fund Advisors now owns 3,911,925 shares of the company’s stock valued at $593,908,000 after buying an additional 340,497 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Becton Dickinson and by 0.6% in the first quarter. Franklin Resources Inc. now owns 3,837,384 shares of the company’s stock valued at $582,591,000 after buying an additional 22,692 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Becton Dickinson and by 20.4% in the first quarter. JPMorgan Chase & Co. now owns 2,300,833 shares of the company’s stock valued at $349,312,000 after buying an additional 389,262 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Becton Dickinson and by 1.7% in the first quarter. Geode Capital Management LLC now owns 1,683,773 shares of the company’s stock valued at $255,101,000 after buying an additional 28,707 shares in the last quarter. Finally, Findlay Park Partners LLP boosted its position in shares of Becton Dickinson and by 22.6% in the first quarter. Findlay Park Partners LLP now owns 1,537,058 shares of the company’s stock valued at $233,356,000 after buying an additional 282,995 shares in the last quarter. 81.96% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Shares of Becton Dickinson and Co. (NYSE:BDX) traded up 0.29% on Wednesday, hitting $176.59. 471,341 shares of the stock traded hands. The stock has a market cap of $37.60 billion, a price-to-earnings ratio of 33.70 and a beta of 0.93. Becton Dickinson and Co. has a one year low of $129.50 and a one year high of $181.76. The company’s 50 day moving average is $176.05 and its 200 day moving average is $168.58.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 4th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.14. The firm had revenue of $3.20 billion for the quarter, compared to analyst estimates of $3.21 billion. Becton Dickinson and had a return on equity of 24.26% and a net margin of 9.24%. Becton Dickinson and’s revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.05 earnings per share. On average, equities analysts forecast that Becton Dickinson and Co. will post $8.56 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 30th. Investors of record on Friday, September 9th were issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 1.50%. The ex-dividend date of this dividend was Wednesday, September 7th. Becton Dickinson and’s payout ratio is currently 50.19%.

BDX has been the topic of a number of recent analyst reports. Leerink Swann reaffirmed a “hold” rating on shares of Becton Dickinson and in a research note on Tuesday, August 9th. Cowen and Company reaffirmed an “outperform” rating and set a $185.00 price target on shares of Becton Dickinson and in a research note on Tuesday, August 16th. Argus reaffirmed a “buy” rating on shares of Becton Dickinson and in a research note on Sunday, June 12th. Citigroup Inc. cut shares of Becton Dickinson and from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $167.00 to $165.00 in a research note on Friday, September 23rd. Finally, Jefferies Group upped their price target on shares of Becton Dickinson and from $190.00 to $192.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $170.82.

In related news, insider Gary M. Cohen sold 29,367 shares of Becton Dickinson and stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $176.81, for a total value of $5,192,379.27. Following the transaction, the insider now owns 125,870 shares of the company’s stock, valued at approximately $22,255,074.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Linda M. Tharby sold 11,704 shares of Becton Dickinson and stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $177.27, for a total value of $2,074,768.08. Following the completion of the transaction, the insider now directly owns 22,146 shares in the company, valued at approximately $3,925,821.42. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

5 Day Chart for NYSE:BDX

Receive News & Stock Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related stocks with our FREE daily email newsletter.